Clinical Trial Update: KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update for KN035 combined with trastuzumab and docetaxel in HER2-positive breast cancer is ongoing (status unknown).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• KN035
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: HER2-positive Breast Cancer | Phase 2 | Status: UNKNOWN